Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis

Patient Preference and Adherence

Volumn 9, Issue , 2015, Pages 777-784

  Zhang, Mingliang ^a   Brenneman, Susan K ^b   Carter, Chureen T ^a   Essoi, Breanna L ^b   Farahi, Kamyar ^a   Johnson, Michael P ^b   Lee, Seina ^a   Olson, William H ^c  

^a Janssen Scientific Affairs LLC   (United States)

^b OPTUM   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Biologic dosing; Biologic treatment; Patient choice; Patient satisfaction; Psoriasis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; ETANERCEPT; METHOTREXATE; USTEKINUMAB;

ADULT; ARTICLE; ATTITUDE ASSESSMENT; BIOLOGICAL THERAPY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT PREFERENCE; PATIENT SATISFACTION; PSORIASIS VULGARIS;

EID: 84936934393     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S85773     Document Type: Article

References (29)

1. National Psoriasis Foundation. Moderate to severe psoriasis and psoriatic arthritis: biologics. Available from: http://www. psoriasis. org/about-psoriasis/treatments/biologics. Accessed March 27, 2015.
2. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014; 70(3): 512-516.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Questions and answers about psoriasis. October 2013. Available from: http://www. niams. nih. gov/Health_Info/Psoriasis/. Accessed March 27, 2015.
4. Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly. 2010; 140: 85-91.
5. Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol. 2010; 162: 1324-1329.
6. Ghatnekar O, Ljungberg, Wirestrand LE, Svensson A. Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden-a cross-sectional study. Eur J Dermatol. 2012; 22: 238-245.
7. Ekelund M, Mallbris L, Qvitzau S, Stenberg B. A higher score on the Dermatology Life Quality Index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis. Acta Derm Venereol. 2013; 93: 684-688.
8. Levy AR, Davie AM, Brazier NC, et al. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012; 51: 1432-1440.
9. Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Pref Adherence. 2013; 7: 199-205.
10. Feldman SR, Malakouti M, Koo JY. Social impact of the burden of psoriasis: effects on patients and practice. Dermatol Online. 2014; 20(8). pii: 13030/qt48r4w8h2.
11. Sandoval LF, Feldman SR. Biologics in practice: adherence to biologic therapy in psoriasis. Dermatologist. 2013; 21(2): 30-34.
12. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg. 2004; 8(5): 310-320.
13. Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Resource use in patients with psoriasis after the introduction of biologics in Sweden. Acta Derm Venereol. 2015; 95(2): 156-161.
14. Uhlenhake EE, Mehregan DA. Ustekinumab: differential use in psoriasis. Clin Cosmet Investig Dermatol. 2011; 4: 93-99.
15. Armstrong AW, Robertson AD, Wu J, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013; 149(10): 1180-1185.
16. Schaarschmidt M-L, Umar N, Schmider, A, et al. Patient preferences for psoriasis treatments: impact of treatment experience. J Eur Acad Dermatol Venereol. 2012; 147(11): 1285-1294.
17. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004; 9: 140-147.
18. Barbosa CD, Balp MM, Kulich K, Germain N, Rofail D. A literature review to explore the link between treatment satisfaction and adherence, compliance, and persistence. Patient Prefer Adherence. 2012; 6: 39-48.
19. Callis Duffin K, Yeung H, Takeshita J, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. Br J Dermatol. 2014; 170(3): 672-680.
20. Puig L. Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapy. Actas Dermosifiliogr. 2014; 105(4): 401-412.
21. Degli Esposti L, Sangiorgi D, Perrone V, et al. Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. Clinicoecon Outcomes Res. 2014; 6: 401-407.
22. Ayala F, Lambert J; on Behalf of the TANGO Study Group. Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: a multicenter, open-label trial (TANGO). J Dermatolog Treat. 2014; 18: 1-8.
23. Umar N, Yamamoto S, Loerbroks A, Terris D. Elicitation and use of patients' preferences in the treatment of psoriasis: a systematic review. Acta Derm Venereol. 2012; 92(4): 341-346.
24. Carter C, Schenkel B, Freedman D, et al. An approach to patient-centered care for patients with psoriatic arthritis. J Am Acad Dermatol. 2013; 68(4): AB192.
25. United States Census Bureau. US Department of Commerce, Economics, and Statistics Administration. Census Regions and Divisions of the United States. Available from: http://www2. census. gov/geo/pdfs/maps-data/maps/reference/us_regdiv. pdf. Accessed March 27, 2015.
26. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification. Last revision 2013. Available from: http://www. cdc. gov/nchs/icd/icd9cm. htm. Accessed March 27, 2015.
27. Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009; 7: 36.
28. SAS Institute Inc. SAS/STAT® 9. 2 User's Guide. Cary, NC, USA: SAS Institute Inc; 2008.
29. Cao Z, Carter C, Wilson KL. Ustekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasis. J Dermatolog Treat. February 20, 2014. [Epub ahead of print].